Logo image of THC

TENET HEALTHCARE CORP (THC) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:THC - US88033G4073 - Common Stock

201.48 USD
-1.87 (-0.92%)
Last: 1/9/2026, 11:28:42 AM
Fundamental Rating

6

THC gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. While THC has a great profitability rating, there are some minor concerns on its financial health. THC may be a bit undervalued, certainly considering the very reasonable score on growth With these ratings, THC could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

In the past year THC was profitable.
In the past year THC had a positive cash flow from operations.
In the past 5 years THC has always been profitable.
In the past 5 years THC always reported a positive cash flow from operatings.
THC Yearly Net Income VS EBIT VS OCF VS FCFTHC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

1.2 Ratios

THC has a Return On Assets of 4.60%. This is in the better half of the industry: THC outperforms 74.26% of its industry peers.
With an excellent Return On Equity value of 33.73%, THC belongs to the best of the industry, outperforming 94.06% of the companies in the same industry.
THC has a better Return On Invested Capital (11.65%) than 85.15% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for THC is in line with the industry average of 9.21%.
The 3 year average ROIC (9.25%) for THC is below the current ROIC(11.65%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.6%
ROE 33.73%
ROIC 11.65%
ROA(3y)4.91%
ROA(5y)3.9%
ROE(3y)50.24%
ROE(5y)332.92%
ROIC(3y)9.25%
ROIC(5y)8.01%
THC Yearly ROA, ROE, ROICTHC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

Looking at the Profit Margin, with a value of 6.49%, THC belongs to the top of the industry, outperforming 85.15% of the companies in the same industry.
THC's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 17.52%, THC belongs to the best of the industry, outperforming 96.04% of the companies in the same industry.
THC's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 82.26%, THC belongs to the best of the industry, outperforming 96.04% of the companies in the same industry.
THC's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 17.52%
PM (TTM) 6.49%
GM 82.26%
OM growth 3Y10.99%
OM growth 5Y11.36%
PM growth 3Y48.9%
PM growth 5YN/A
GM growth 3Y-0.23%
GM growth 5Y-0.27%
THC Yearly Profit, Operating, Gross MarginsTHC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

5

2. Health

2.1 Basic Checks

THC has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for THC has been reduced compared to 1 year ago.
THC has less shares outstanding than it did 5 years ago.
The debt/assets ratio for THC has been reduced compared to a year ago.
THC Yearly Shares OutstandingTHC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
THC Yearly Total Debt VS Total AssetsTHC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

THC has an Altman-Z score of 1.87. This is not the best score and indicates that THC is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.87, THC is in line with its industry, outperforming 43.56% of the companies in the same industry.
The Debt to FCF ratio of THC is 8.78, which is on the high side as it means it would take THC, 8.78 years of fcf income to pay off all of its debts.
With a Debt to FCF ratio value of 8.78, THC perfoms like the industry average, outperforming 49.51% of the companies in the same industry.
A Debt/Equity ratio of 3.26 is on the high side and indicates that THC has dependencies on debt financing.
THC's Debt to Equity ratio of 3.26 is on the low side compared to the rest of the industry. THC is outperformed by 75.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.26
Debt/FCF 8.78
Altman-Z 1.87
ROIC/WACC1.32
WACC8.81%
THC Yearly LT Debt VS Equity VS FCFTHC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

A Current Ratio of 1.71 indicates that THC should not have too much problems paying its short term obligations.
With a decent Current ratio value of 1.71, THC is doing good in the industry, outperforming 68.32% of the companies in the same industry.
THC has a Quick Ratio of 1.64. This is a normal value and indicates that THC is financially healthy and should not expect problems in meeting its short term obligations.
THC has a Quick ratio of 1.64. This is in the better half of the industry: THC outperforms 66.34% of its industry peers.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.64
THC Yearly Current Assets VS Current LiabilitesTHC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

5

3. Growth

3.1 Past

THC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.32%, which is quite impressive.
The Earnings Per Share has been growing by 34.84% on average over the past years. This is a very strong growth
Looking at the last year, THC shows a decrease in Revenue. The Revenue has decreased by -0.56% in the last year.
Measured over the past years, THC shows a small growth in Revenue. The Revenue has been growing by 2.26% on average per year.
EPS 1Y (TTM)39.32%
EPS 3Y16.22%
EPS 5Y34.84%
EPS Q2Q%26.28%
Revenue 1Y (TTM)-0.56%
Revenue growth 3Y1.98%
Revenue growth 5Y2.26%
Sales Q2Q%3.26%

3.2 Future

The Earnings Per Share is expected to grow by 13.65% on average over the next years. This is quite good.
THC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.27% yearly.
EPS Next Y36.76%
EPS Next 2Y18.31%
EPS Next 3Y15.68%
EPS Next 5Y13.65%
Revenue Next Year2.31%
Revenue Next 2Y3.35%
Revenue Next 3Y3.88%
Revenue Next 5Y3.27%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
THC Yearly Revenue VS EstimatesTHC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B 20B 25B
THC Yearly EPS VS EstimatesTHC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5 10 15 20

8

4. Valuation

4.1 Price/Earnings Ratio

THC is valuated correctly with a Price/Earnings ratio of 12.98.
84.16% of the companies in the same industry are more expensive than THC, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of THC to the average of the S&P500 Index (27.00), we can say THC is valued rather cheaply.
The Price/Forward Earnings ratio is 12.10, which indicates a correct valuation of THC.
Compared to the rest of the industry, the Price/Forward Earnings ratio of THC indicates a rather cheap valuation: THC is cheaper than 86.14% of the companies listed in the same industry.
THC's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.70.
Industry RankSector Rank
PE 12.98
Fwd PE 12.1
THC Price Earnings VS Forward Price EarningsTHC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, THC is valued cheaply inside the industry as 90.10% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, THC is valued cheaply inside the industry as 82.18% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 11.79
EV/EBITDA 6.27
THC Per share dataTHC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 200

4.3 Compensation for Growth

THC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
THC has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as THC's earnings are expected to grow with 15.68% in the coming years.
PEG (NY)0.35
PEG (5Y)0.37
EPS Next 2Y18.31%
EPS Next 3Y15.68%

0

5. Dividend

5.1 Amount

No dividends for THC!.
Industry RankSector Rank
Dividend Yield 0%

TENET HEALTHCARE CORP

NYSE:THC (1/9/2026, 11:28:42 AM)

201.48

-1.87 (-0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)10-28 2025-10-28/bmo
Earnings (Next)02-10 2026-02-10/amc
Inst Owners98.45%
Inst Owner Change0%
Ins Owners0.73%
Ins Owner Change-1.09%
Market Cap17.71B
Revenue(TTM)20.86B
Net Income(TTM)1.35B
Analysts81.43
Price Target238.92 (18.58%)
Short Float %3.08%
Short Ratio2.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.75%
Min EPS beat(2)10.92%
Max EPS beat(2)38.59%
EPS beat(4)4
Avg EPS beat(4)25.46%
Min EPS beat(4)10.92%
Max EPS beat(4)38.59%
EPS beat(8)8
Avg EPS beat(8)41.73%
EPS beat(12)12
Avg EPS beat(12)37.25%
EPS beat(16)16
Avg EPS beat(16)44.64%
Revenue beat(2)1
Avg Revenue beat(2)0.42%
Min Revenue beat(2)-0.28%
Max Revenue beat(2)1.13%
Revenue beat(4)2
Avg Revenue beat(4)-0.36%
Min Revenue beat(4)-2.85%
Max Revenue beat(4)1.13%
Revenue beat(8)6
Avg Revenue beat(8)0.46%
Revenue beat(12)9
Avg Revenue beat(12)0.73%
Revenue beat(16)9
Avg Revenue beat(16)-0.03%
PT rev (1m)1.93%
PT rev (3m)17.61%
EPS NQ rev (1m)-0.2%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.04%
EPS NY rev (3m)2.9%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)1.71%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.66%
Valuation
Industry RankSector Rank
PE 12.98
Fwd PE 12.1
P/S 0.85
P/FCF 11.79
P/OCF 7.15
P/B 4.41
P/tB N/A
EV/EBITDA 6.27
EPS(TTM)15.52
EY7.7%
EPS(NY)16.66
Fwd EY8.27%
FCF(TTM)17.09
FCFY8.48%
OCF(TTM)28.19
OCFY13.99%
SpS237.29
BVpS45.67
TBVpS-96.62
PEG (NY)0.35
PEG (5Y)0.37
Graham Number126.29
Profitability
Industry RankSector Rank
ROA 4.6%
ROE 33.73%
ROCE 14.7%
ROIC 11.65%
ROICexc 13.23%
ROICexgc 30.88%
OM 17.52%
PM (TTM) 6.49%
GM 82.26%
FCFM 7.2%
ROA(3y)4.91%
ROA(5y)3.9%
ROE(3y)50.24%
ROE(5y)332.92%
ROIC(3y)9.25%
ROIC(5y)8.01%
ROICexc(3y)10.01%
ROICexc(5y)8.76%
ROICexgc(3y)21.74%
ROICexgc(5y)18.93%
ROCE(3y)11.67%
ROCE(5y)10.11%
ROICexgc growth 3Y12.5%
ROICexgc growth 5Y15.11%
ROICexc growth 3Y10.5%
ROICexc growth 5Y10.87%
OM growth 3Y10.99%
OM growth 5Y11.36%
PM growth 3Y48.9%
PM growth 5YN/A
GM growth 3Y-0.23%
GM growth 5Y-0.27%
F-Score5
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 3.26
Debt/FCF 8.78
Debt/EBITDA 2.93
Cap/Depr 118.3%
Cap/Sales 4.68%
Interest Coverage 4.59
Cash Conversion 55.34%
Profit Quality 110.93%
Current Ratio 1.71
Quick Ratio 1.64
Altman-Z 1.87
F-Score5
WACC8.81%
ROIC/WACC1.32
Cap/Depr(3y)96.91%
Cap/Depr(5y)86.14%
Cap/Sales(3y)4.04%
Cap/Sales(5y)3.71%
Profit Quality(3y)126.2%
Profit Quality(5y)239.34%
High Growth Momentum
Growth
EPS 1Y (TTM)39.32%
EPS 3Y16.22%
EPS 5Y34.84%
EPS Q2Q%26.28%
EPS Next Y36.76%
EPS Next 2Y18.31%
EPS Next 3Y15.68%
EPS Next 5Y13.65%
Revenue 1Y (TTM)-0.56%
Revenue growth 3Y1.98%
Revenue growth 5Y2.26%
Sales Q2Q%3.26%
Revenue Next Year2.31%
Revenue Next 2Y3.35%
Revenue Next 3Y3.88%
Revenue Next 5Y3.27%
EBIT growth 1Y14.33%
EBIT growth 3Y13.18%
EBIT growth 5Y13.88%
EBIT Next Year44.53%
EBIT Next 3Y16.02%
EBIT Next 5Y9.84%
FCF growth 1Y31.99%
FCF growth 3Y7.04%
FCF growth 5Y14.67%
OCF growth 1Y25.72%
OCF growth 3Y9.29%
OCF growth 5Y10.67%

TENET HEALTHCARE CORP / THC FAQ

What is the ChartMill fundamental rating of TENET HEALTHCARE CORP (THC) stock?

ChartMill assigns a fundamental rating of 6 / 10 to THC.


What is the valuation status for THC stock?

ChartMill assigns a valuation rating of 8 / 10 to TENET HEALTHCARE CORP (THC). This can be considered as Undervalued.


Can you provide the profitability details for TENET HEALTHCARE CORP?

TENET HEALTHCARE CORP (THC) has a profitability rating of 9 / 10.


What is the valuation of TENET HEALTHCARE CORP based on its PE and PB ratios?

The Price/Earnings (PE) ratio for TENET HEALTHCARE CORP (THC) is 12.98 and the Price/Book (PB) ratio is 4.41.


Can you provide the expected EPS growth for THC stock?

The Earnings per Share (EPS) of TENET HEALTHCARE CORP (THC) is expected to grow by 36.76% in the next year.